Skip to main content
HealthcareNovember 2026 3 min read

Healthcare Dealmaking Pauses in Q3: KKR's $5.7 Billion Integer Take-Private Leads a Slower Quarter

Healthcare Dealmaking Pauses in Q3: KKR's $5.7 Billion Integer Take-Private Leads a Slower Quarter

Sikich's Q3 2026 update describes a pause in US healthcare dealmaking, not a reversal. Healthcare M&A totaled $66.5 billion in Q3, down 48% from Q2's $128.5 billion but up 17% from Q3 2025. Year-to-date value reached $291 billion, already 84% of 2025's full-year total of $344.9 billion, which puts 2026 on track for the strongest year since 2021.

Private equity drove much of the quarter. KKR's $5.7 billion take-private of Integer Holdings was the largest healthcare buyout, followed by Apax's $1.7 billion carve-out of Gerresheimer's Centor packaging unit. Strategics, particularly in biopharma, are doing the largest deals as higher borrowing costs make leveraged transactions harder.

Three forces shaped the quarter, per Sikich: rising rates, approaching federal reimbursement cuts and sustained regulatory scrutiny. The FTC formed a Healthcare Task Force in March 2026 to coordinate competition and consumer-protection work across the sector. Behavioral health, maternity and long-term care are especially exposed because of Medicaid-dependent payer mixes.

The longer arc is a pivot rather than a retreat. Health Capital Topics, citing PitchBook data, shows PE investment in physician practice management falling from 851 transactions in 2021 to 105 in the first half of 2026, as sponsors move away from leveraged physician roll-ups toward larger, later-stage and asset-backed targets. Bain notes that creative structures, including take-privates, featured prominently in the first half.

What it means for hiring

- Healthcare investors need regulatory fluency. Antitrust and reimbursement risk now sit at the center of underwriting. - Operating talent is the differentiator. With multiple expansion no longer enough, sponsors want healthcare operators who can drive margin. - Take-private and carve-out experience is in demand. Larger, more complex targets require more seasoned deal teams.

Talk to us

If you are building a healthcare investing team or searching for a healthcare operating partner or portfolio CEO, we would like to hear from you.

Phone: 857-400-8321 LinkedIn: https://www.linkedin.com/in/armat1/

Interested in discussing these insights further?

Get In Touch